Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | RAB9A | P51151 | 4/20 | 0.33 |
| ▸ | LMNA | P02545 | 4/20 | 0.33 |
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3873505 | 1.00 | ALDH1A1 (0.33) | ALDH1A1RAB9ALMNANPC1KMT2A | |
| SCHEMBL3873512 | 1.00 | ALDH1A1 (0.33) | ALDH1A1RAB9ALMNANPC1KMT2A | |
| SCHEMBL10454264 | 0.92 | KMT2A (0.30) | KMT2A | |
| SCHEMBL3871044 | 0.86 | CYP1A2 (0.37) | ALDH1A1LMNAKMT2AGAAMEN1 | |
| SCHEMBL3871042 | 0.86 | CYP1A2 (0.37) | ALDH1A1LMNAKMT2AGAAMEN1 | |
| SCHEMBL3871047 | 0.86 | CYP1A2 (0.37) | ALDH1A1LMNAKMT2AGAAMEN1 | |
| SCHEMBL3863861 | 0.84 | TSHR (0.36) | ALDH1A1RAB9AKMT2AHPGDMEN1 | |
| SCHEMBL3863855 | 0.84 | TSHR (0.36) | ALDH1A1RAB9AKMT2AHPGDMEN1 | |
| SCHEMBL3863858 | 0.84 | TSHR (0.36) | ALDH1A1RAB9AKMT2AHPGDMEN1 | |
| SCHEMBL3870916 | 0.81 | POLB (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1845078-B1 | PROCESS FOR PRODUCING LARGE CYCLIC KETONE AND INTERMEDIATE THEREFOR | TAKASAGO PERFUMERY CO LTD (JP) | 2017-06-07 | — | — | EP | disclosed |
| US-7479574-B2 | Method of producing macrocyclic ketone, and intermediate thereof | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2009-01-20 | — | — | US | disclosed |
| US-20070287870-A1 | Method of Producing Macrocyclic Ketone, and Intermediate Thereof | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-12-13 | — | — | US | disclosed |
| EP-1845078-A1 | PROCESS FOR PRODUCING LARGE CYCLIC KETONE AND INTERMEDIATE THEREFOR | Takasago International Corporation (JP) | 2007-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287870-A1 | Method of Producing Macrocyclic Ketone, and Intermediate Thereof | MSMO1, CYP17A1, DNMT1 | ALDH1A1 171/4885RAB9A 3739/4885LMNA 2057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.